Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised EQT AB (publ) in connection with the listing on Nasdaq Stockholm (1)
Mandate

Vinge has advised EQT AB (publ) in connection with the listing on Nasdaq Stockholm

September 24, 2019 Capital Markets and Public M&A

Vinge has advised EQT AB (publ) (“EQT”) in connection with the offering and listing on Nasdaq Stockholm with first day of trading on 24 September 2019.

Vinge has advised EQT in connection with the listing and also with the connected reorganization. 


The Vinge team primarily consisted of Dain Hård Nevonen, Erik Sjöman, Sofie Bjärtun, Joel Wahlberg, Hampus Olsson, Joel Magnusson and Emelie Svanberg (Capital Markets), Christina Kokko, Filip Öhrner, Karl Klackenberg, Christian Brelin and Christina Odengran (M&A and Restructuring), Louise Brorsson Salomon, Josefine Larsson, Ludvig Wettergren and Pauline Lagerstrand (Banking and Finance), Mattias Schömer, Henrik Wastenson and Victor Ericsson (Tax), Marcus Glader and Emma Johansson (Competition and Regulatory) and Olof Jisland and Valter Gran (EQT Foundation).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025